TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20970233

Group type: EXPERIMENTAL
Intervention: Intervention leaflet
Number of subjects: 104

Group type: COMPARATOR
Intervention: Foundation leaflet (control)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Local food leaflet (control)
Number of subjects: 104
Study: 18363884

Group type: EXPERIMENTAL
Intervention: GH-treatment (1 mg/m²/day) in infants (n=20) for 1 year
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: GH-treatment (1 mg/m²/day) in children > 3 years (n=27) for 2 years
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no treatment) in infants (n=22) for 1 year
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no treatment) in children > 3 years (n=22) for 2 years
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: GH-treatment (1 mg/m²/day) in infants and children
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: GH-treatment (1 mg/m²/day) in children
Number of subjects: 91
Study: 15957834

Group type: EXPERIMENTAL
Intervention: Sodium ferulate (SF) treatment for 4 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 102
Study: 12060619

Group type: EXPERIMENTAL
Intervention: PSA RT-PCR
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PSMA RT-PCR
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PSCA RT-PCR
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PSCA PCR
Number of subjects: 129
Study: 10548762

Group type: EXPERIMENTAL
Intervention: Cellasene
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (Colonease)
Number of subjects: 11
Study: 7703389

Group type: EXPERIMENTAL
Intervention: Endothelin (2.5 ng/kg per minute for 90 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-Arginine (5 mg/kg per minute for 90 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of endothelin and L-arginine
Number of subjects: 0
Study: 2283626

Group type: EXPERIMENTAL
Intervention: CT pelvimetry
Number of subjects: 50

Group type: COMPARATOR
Intervention: Classical pelvimetry
Number of subjects: 50
Study: 373560

Group type: EXPERIMENTAL
Intervention: Administration sets changed every 24 hours
Number of subjects: 300

Group type: COMPARATOR
Intervention: Administration sets changed every 48 hours
Number of subjects: 300
Study: 7039276

Group type: EXPERIMENTAL
Intervention: lopamidol 61% as the contrast medium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conray
Number of subjects: 100
Study: 30843481

Group type: EXPERIMENTAL
Intervention: HIV-positive individuals
Number of subjects: 49
Study: 30037647

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis once daily for 12 months
Number of subjects: 404

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 404
Study: 26957117

Group type: EXPERIMENTAL
Intervention: IntelliVent®‐ASV
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 80
Study: 24599461

Group type: EXPERIMENTAL
Intervention: Chronic forced use of the nondominant hand (left hand)
Number of subjects: 8
Study: 22503174

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 42
Study: 20178563

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for 8 weeks and 10 mg for the next 4 months (AF group)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg daily for 8 weeks and 10 mg for the next 4 months (non-AF group)
Number of subjects: 69
Study: 17503876

Group type: EXPERIMENTAL
Intervention: Endurance training and long‐acting bronchodilatators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance training and technical modalities (inspiratory pressure support and inspiratory muscle training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interval training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcutaneous neuromuscular electrical stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise training and supplements (oxygen, oral creatine, anabolic steroids and polyunsaturated fatty acids)
Number of subjects: 0
Study: 16037110

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 mg every 3 h for a maximum of five doses
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral misoprostol 400 mg every 3 h for a maximum of five doses
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 120
Study: 12386040

Group type: EXPERIMENTAL
Intervention: Screening and brief intervention for excessive alcohol use
Number of subjects: 24
Study: 10431992

Group type: EXPERIMENTAL
Intervention: Limited anterior plication (LAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Superficial vein surgery (ligation and section of the major incompetent superficial veins)
Number of subjects: 0
Study: 7748753

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 2 weeks
Number of subjects: 190

Group type: COMPARATOR
Intervention: Itraconazole 100 mg/day for 4 weeks
Number of subjects: 190
Study: 2407757

Group type: EXPERIMENTAL
Intervention: 0.1% octenidine mouthrinse
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control mouthrinse (placebo)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 451
Study: 444785

Group type: EXPERIMENTAL
Intervention: Schizophrenic speech
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal speech
Number of subjects: 20
Study: 30049402

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Participation in organized sports
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Parental leisure-time physical activity
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Parental traffic safety perceptions
Number of subjects: 738
Study: 28031378

Group type: EXPERIMENTAL
Intervention: High-emotion graphic warnings
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Low-emotion graphic warnings
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 1205
Study: 25479804

Group type: EXPERIMENTAL
Intervention: Self-collected HPV testing
Number of subjects: 5109

Group type: COMPARATOR
Intervention: Clinician-collected HPV testing
Number of subjects: 5109
Study: 24427672

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 mcg/day plus oral Levocetirizine 5 mg/day (n: 21)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 mcg/day plus oral Montelukast 10 mg/day (n: 21)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Topical Mometasone furoate 200 mcg/day (n: 14)
Number of subjects: 56
Study: 21088253

Group type: EXPERIMENTAL
Intervention: Atazanavir treatment (3-day duration)
Number of subjects: 16
Study: 18440147

Group type: EXPERIMENTAL
Intervention: 40% menthol solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20% cinnamaldehyde solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0
Study: 16848645

Group type: EXPERIMENTAL
Intervention: Bupropion XL 300 to 450 mg/day
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 14572572

Group type: EXPERIMENTAL
Intervention: Prednisolone therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Mesalamine (4 g o.d.)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 10846036

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplementation at 4 g/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplementation + 60 min of exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control trial (fat meal, 100 g fat)
Number of subjects: 12
Study: 10178487

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrical cardioversion (EC)
Number of subjects: 0
Study: 8348062

Group type: EXPERIMENTAL
Intervention: Beta-carotene and retinol; specific dosages not mentioned; duration of intervention not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo; specific details not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable; no specific intervention mentioned.
Number of subjects: 0
Study: 2878747

Group type: EXPERIMENTAL
Intervention: SMS 201-995, 50 micrograms, twice daily subcutaneous injection
Number of subjects: 6
Study: 30373463

Group type: EXPERIMENTAL
Intervention: DREAMS:START intervention to improve sleep for people living with dementia; details on dosage and duration not specified.
Number of subjects: 0
Study: 27274151

Group type: EXPERIMENTAL
Intervention: Probiotic rinse
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Herbal oral rinse
Number of subjects: 60
Study: 25778646

Group type: EXPERIMENTAL
Intervention: Levocarnitine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no levocarnitine)
Number of subjects: 0
Study: 22944595

Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation (TSF) treatment
Number of subjects: 966
Study: 20965928

Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin once daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 30
Study: 19469405

Group type: EXPERIMENTAL
Intervention: Infiltrative anaesthesia (gLA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: General anaesthesia (gGA)
Number of subjects: 76
Study: 16878210

Group type: EXPERIMENTAL
Intervention: Cylindrical CVD bur
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spherical CVD bur
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CVD burs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dentin substrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enamel substrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direction of handpiece motion
Number of subjects: 40
Study: 12926056

Group type: EXPERIMENTAL
Intervention: H. pylori eradication in patients with chronic gastritis (N = 50)
Number of subjects: 95

Group type: COMPARATOR
Intervention: H. pylori-positive non-metaplastic gastritis
Number of subjects: 95

Group type: COMPARATOR
Intervention: H. pylori-positive intestinal metaplasia
Number of subjects: 95

Group type: COMPARATOR
Intervention: Intestinal-type adenocarcinoma
Number of subjects: 95
Study: 11204965

Group type: EXPERIMENTAL
Intervention: Low pressure tourniquet system (250 mmHg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: High pressure tourniquet system (350 mmHg)
Number of subjects: 31
Study: 8803586

Group type: EXPERIMENTAL
Intervention: Group II B (no spontaneous angina at rest in 48 hours prior to PTCA)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Group III B (presence of spontaneous angina at rest in 48 hours prior to PTCA)
Number of subjects: 188
Study: 1555310

Group type: EXPERIMENTAL
Intervention: Guillotine tonsillectomy
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Dissection tonsillectomy
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Age group 16-25 years
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Month of operation (May to July)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Method of haemostasis, surgical experience, and premedication
Number of subjects: 1090
Study: 6425917

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard tricyclic antidepressants
Number of subjects: 0
Study: 30852547

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy (90 mg twice daily) after 1-month DAPT
Number of subjects: 7585

Group type: COMPARATOR
Intervention: Standard regimen of DAPT for 12 months followed by aspirin monotherapy
Number of subjects: 7585
Study: 28884877

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure (n=15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sleep hygiene education (n=16)
Number of subjects: 31
Study: 26990142

Group type: EXPERIMENTAL
Intervention: Mentoring program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine training with faculty supervision (Control)
Number of subjects: 60
Study: 25268306

Group type: EXPERIMENTAL
Intervention: Over-the-scope clip (OTSC) system for anchoring self-expanding metal stents (SEMS)
Number of subjects: 12
Study: 21912876

Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic surgery
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard laparoscopic surgery
Number of subjects: 400
Study: 20052723

Group type: COMPARATOR
Intervention: Lifetime pack-years 0-10
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Lifetime pack-years 10-20
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Lifetime pack-years 20+
Number of subjects: 1045

Group type: COMPARATOR
Intervention: 12+ pack-years before age 30 years
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Past smokers
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 1045
Study: 17693371

Group type: EXPERIMENTAL
Intervention: Self-ligating bracket (Damon 2)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional edgewise appliance (Microarch)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Self-ligating group
Number of subjects: 54
Study: 16225499

Group type: EXPERIMENTAL
Intervention: Nifuratel (15 mg/kg/day, q.d.s.)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Furazolidone (10 mg/kg/day, q.d.s.)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Furazolidone
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Nifuratel
Number of subjects: 76
Study: 11961630

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 60
Study: 10404953

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8527292

Group type: EXPERIMENTAL
Intervention: MK-0476 20 to 800 mg single oral doses
Number of subjects: 18

Group type: COMPARATOR
Intervention: 200 mg MK-0476 as a solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: 200 mg MK-0476 capsules after a standard breakfast
Number of subjects: 18
Study: 1526087

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/ml) in methyl cellulose gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (methyl cellulose alone)
Number of subjects: 12
Study: 3887445

Group type: EXPERIMENTAL
Intervention: Clomipramine (CLI)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Imipramine (IMI)
Number of subjects: 23
Study: 31209097

Group type: EXPERIMENTAL
Intervention: HARPdoc intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Blood Glucose Awareness Training (Control)
Number of subjects: 96
Study: 29321337

Group type: EXPERIMENTAL
Intervention: Higher clot burden score (B=0.063; 95% CI, 0.008-0.118)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Higher thrombus attenuation increase (B=0.014; 95% CI, 0.003-0.026)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Collateral score
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Thrombus perviousness scores
Number of subjects: 195
Study: 26555592

Group type: EXPERIMENTAL
Intervention: Single-pass dissection using a motor-driven linear microkeratome system
Number of subjects: 48
Study: 23933474

Group type: EXPERIMENTAL
Intervention: Brain Fitness (BF - auditory perception)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Space Fortress (SF - visuomotor/working memory)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rise of Nations (RON - strategic reasoning)
Number of subjects: 42
Study: 23080240

Group type: EXPERIMENTAL
Intervention: Shear-reducing insole
Number of subjects: 299

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 299
Study: 20090348

Group type: EXPERIMENTAL
Intervention: Thermoreversible wound gel containing polyhexanide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Flammazine (control)
Number of subjects: 44
Study: 18362418

Group type: EXPERIMENTAL
Intervention: Aggressive therapy aiming for targets of <120/80 mmHg and <80 mg/dl for blood pressure and LDL-C respectively.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard therapy aiming for blood pressure <140/90 mmHg and LDL-C <100 mg/dl.
Number of subjects: 500
Study: 16485520

Group type: EXPERIMENTAL
Intervention: Strength Training (ST) for 21 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nutritional Counseling (NC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Strength Training (ST) + Nutritional Counseling (NC)
Number of subjects: 50
Study: 12095184

Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 18

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 18
Study: 9566821

Group type: EXPERIMENTAL
Intervention: Abdominal lymphoadenomegaly present
Number of subjects: 86

Group type: COMPARATOR
Intervention: Abdominal lymphoadenomegaly absent
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Subjects with abdominal lymphoadenomegaly
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Presence of HCV RNA
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Presence of gamma-globulin
Number of subjects: 86
Study: 8154311

Group type: EXPERIMENTAL
Intervention: Calcium plus 50 IU/day, 5 days per week of nasal salmon calcitonin
Number of subjects: 287

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 287
Study: 3121165

Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion with mitomycin C (CHPP‐M)
Number of subjects: 64
Study: 31462727

Group type: EXPERIMENTAL
Intervention: Soursop supplementation (2 × 100 g soursop fruit juice per day for 3 months)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Soursop supplementation
Number of subjects: 143
Study: 29454333

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block (PVB) with 0.5% bupivacaine, 15 mL
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intravenous tramadol, loading dose of 1 mg/kg
Number of subjects: 53
Study: 26440201

Group type: COMPARATOR
Intervention: Ti implants (4.1 mm diameter)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ti‐Zr implants (3.3 mm diameter)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both Ti and Ti‐Zr implants
Number of subjects: 40
Study: 24163236

Group type: EXPERIMENTAL
Intervention: Home telehealth intervention (telephone counselling and home Internet‐enabled digital video recorders)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Monthly telephone counselling (control)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Home telehealth intervention
Number of subjects: 88
Study: 20946990

Group type: EXPERIMENTAL
Intervention: 8-week Yoga of Awareness program (gentle poses, meditation, breathing exercises, yoga-based coping instructions, group discussions)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wait-listed standard care
Number of subjects: 53
Study: 18179556

Group type: EXPERIMENTAL
Intervention: IL-6 in wound fluids
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: TNFalpha in wound fluids
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IL-6 at cut-off of 125 pg/ml
Number of subjects: 45

Group type: COMPARATOR
Intervention: CRP and LBP (serological markers)
Number of subjects: 45
Study: 16598749

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 451

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 451
Study: 12702979

Group type: EXPERIMENTAL
Intervention: Triple therapy with rabeprazole, clarithromycin, and tinidazole plus lactoferrin for 7 days (group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Triple therapy with rabeprazole, clarithromycin, and tinidazole for 7 days (group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Triple therapy with rabeprazole, clarithromycin, and tinidazole for 10 days (group C)
Number of subjects: 150
Study: 10924316

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 9411221

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Antiarrhythmic-drug therapy (primarily amiodarone)
Number of subjects: 1016
Study: 8377779

Group type: EXPERIMENTAL
Intervention: 5,6-benzo-[alpha]-pyrone (400 mg for six months)
Number of subjects: 52
Study: 2439814

Group type: EXPERIMENTAL
Intervention: bopindolol 1 mg
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: bopindolol 2 mg
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: atenolol 50 mg
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 257

Group type: COMPARATOR
Intervention: bopindolol
Number of subjects: 257

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 257
Study: 30425460

Group type: EXPERIMENTAL
Intervention: Cognitive function assessed using the mini-mental state examination (MMSE) score
Number of subjects: 163

Group type: COMPARATOR
Intervention: Bottom category of MMSE score
Number of subjects: 163
Study: 27773406

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 24880197

Group type: EXPERIMENTAL
Intervention: Cognitive functioning and physical capacity assessed after 13 weeks of CRC supplementation (2.5 g per day of chicken meat extract containing 40% CRC components).
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Senior Fitness Test scores after CRC supplementation.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Perceived exertion levels before and after supplementation in the CRC group.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: STMS scores in the CRC group.
Number of subjects: 56
Study: 22644963

Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6% dosed twice daily
Number of subjects: 496

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 496